To find a sales consultant, please complete the form below or if you are currently a Sculptra Aesthetic customer, please call 1-888-SCULPTRA (1-888-728-5787). For all other inquiries, including reporting of an adverse medical
reaction to a Valeant product, please contact us.

Unfortunately, due to the large number of requests for training, not all training requests can be fulfilled in every geographic area.

If you have filled out a Sculptra Aesthetic sales consultant request, and you are certified by one of the boards described, you will be contacted to discuss your request for more information about Sculptra Aesthetic.

Required fields are marked with an asterisk (*).

CONTACT information

PRIMARY PRACTICE details

*

First name:

*

Last name:

*

Title:

*

Specialty:

*

Email address:

*

Phone number:

*

Practice name:

*

Address 1:

Address 2:

*

City:

*

State:

*

Zip code:

INTENDED USE / INDICATIONS

Sculptra® Aesthetic is indicated for use in immune-competent people as a single regimen for correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in which deep dermal grid pattern (cross-hatch) injection technique is appropriate. (This corresponds to Wrinkle Assessment Scores (WAS) of 2 to 4 in Figure 2 and the cross-hatch injection technique presented in Figures 3-7 in the Instructions for Use Section of the full Prescribing Information).

IMPORTANT SAFETY INFORMATION FOR SCULPTRA AESTHETIC

Sculptra Aesthetic is contraindicated in individuals with known hypersensitivity to any of its components or in patients with known history of or susceptibility to keloid formation or hypertrophic scarring. It should not be injected in areas with active skin infection or inflammation. Avoid injection into the blood vessels or the lips. Use in the periorbital area is not recommended. Do not overcorrect (overfill) the contour deficiency due to the gradual treatment effect.

Adverse events include immediate and transient injection-related adverse events such as bleeding from the injection site, discomfort, erythema or inflammation, ecchymosis, pruritus, and edema. Other adverse events include the delayed occurrence of subcutaneous papules, which were confined to the injection site and were typically palpable, asymptomatic, and non-visible. Visible nodules, some with delayed onset with or without inflammation or skin discoloration, have also been reported. In the clinical studies the numbers of papules and nodules were low and most resolved without treatment.